Rallis, a subsidiary of Tata Chemicals, has established a reputation of being a trusted solutions provider for agri-inputs, globally, with an accent on innovation, a thorough knowledge of farm science and a penetrative distribution network. Lal was picked up from Tata Chemicals, another Tata Group company where he was the Chief Operating Officer (India Chemicals Business).
Lal brings more than 37 years of experience to the table having worked at Hindustan Lever and Tata Chemicals. At the time of his appointment, the company’s chairman, Bhaskar Bhat had said: “I am pleased to welcome Lal to the Rallis family. Lal brings with him a depth of manufacturing and operational experience, business expertise and knowledge of process chemistry — all of which would be hugely useful in Rallis’ future journey.”
Serving Farmers Via Science
Incorporated in 1948, Rallis India is engaged in the business of manufacture and marketing of agri inputs. From a solo play on agrochemicals, the company has grown to make its presence felt across the value chain of agriculture inputs — right from seeds to organic plant growth nutrients along with a suite of practices and services. Rallis has evolved its innovation strategy on 'Serving Farmers through Science'. Accordingly, it develops innovative solutions to enable farmers to improve their productivity.
The company has a strong distribution network of more than 6,000 dealers and over 70,000 retailers. It reaches a vast multitude of India's farmers covering 80 per cent of the districts and exports to more than 58 countries.
For the fiscal year 2021-22, the company’s gross revenue grew 7.2 per cent to Rs 2,603.93 crore. In FY21, it was Rs 2,429 crore. Commenting on the financials, Lal said: “The company delivered a resilient performance in the wake of multiple headwinds during the year. Our domestic crop care business grew 14 per cent and exports 6.2 per cent during the year.”
The company’s seeds business faced challenges and revenue fell 13 per cent during FY2022. Lal said the supply chain challenges continued into Q4 with availability issues for certain intermediates as well as steep cost inflation